AA
APGE icon

AlphaCentric Advisors’s Apogee Therapeutics APGE Stock Holding History

AlphaCentric Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
11,533
+164
+1% +$14.8K 1.3% 10
2026
Q1 		$957K Buy
11,369
+618
+6% +$44.9K 0.96% 21
2025
Q4 		$811K Buy
+10,751
New +$677K 0.81% 29
2024
Q4 		$256K Sell
5,649
-2,851
-34% -$145K 0.26% 100
2024
Q3 		$499K Buy
+8,500
New +$407K 0.37% 76

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

AlphaCentric Advisors's APGE Position: Q2 2026 in Review

AlphaCentric Advisors increased its Apogee Therapeutics (APGE) stake by 1.4% in Q2 2026, buying an estimated $14.8K and bringing the position to 11,533 shares worth $1.53M. The position accounts for 1.3% of the portfolio, ranked #10.

AlphaCentric Advisors first reported a position in APGE in Q3 2024 and has held it in 5 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • AlphaCentric Advisors held 11,533 shares of Apogee Therapeutics worth $1.53M as of Q2 2026.
  • AlphaCentric Advisors bought 164 Apogee Therapeutics shares in Q2 2026, an estimated $14.8K.
  • Apogee Therapeutics made up 1.3% of AlphaCentric Advisors's portfolio in Q2 2026, its #10 holding.
  • AlphaCentric Advisors first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.